Compare VYX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VYX | OCS |
|---|---|---|
| Founded | 1881 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | VYX | OCS |
|---|---|---|
| Price | $6.56 | $25.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $14.64 | ★ $41.86 |
| AVG Volume (30 Days) | ★ 2.3M | 372.9K |
| Earning Date | 05-07-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $466.06 |
| Revenue Next Year | N/A | $502.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.46 | $14.00 |
| 52 Week High | $14.67 | $30.68 |
| Indicator | VYX | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 30.82 | 38.36 |
| Support Level | $6.46 | $19.00 |
| Resistance Level | $10.24 | $29.19 |
| Average True Range (ATR) | 0.35 | 1.31 |
| MACD | -0.02 | -0.39 |
| Stochastic Oscillator | 4.22 | 1.92 |
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in three reportable segments: Retail, Restaurants, and Digital Banking. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The Digital Banking segment serves financial institutions with cloud-based software solutions for a fully integrated digital banking experience across channels. Revenue sources include software sales and service support within each segment.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.